Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116753 · ClinicalTrials.gov registry record · Phase 2
A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 460
- Enrollment target
NCT00116753 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 460 participants.
The verdict
NCT00116753, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 460 participants
- Enrollment target
Study Summary
The rationale of the study was to evaluate different degarelix dosing regimens for a three-month interval that was to produce and maintain castration in prostate cancer patients through immediate and prolonged testosterone suppression, and to provide confirmatory evidence of the safety of degarelix.
Interventions
- DRUG Degarelix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116753
The ClinicalTrials.gov registry entry for NCT00116753 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Degarelix is the first listed.
NCT00116753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116753 about?
NCT00116753 is a clinical study titled "A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer". The rationale of the study was to evaluate different degarelix dosing regimens for a three-month interval that was to produce and maintain castration in prostate cancer patients through immediate and prolonged testosterone suppression, and to provide confirmatory evidence of the safety of degarelix.
What is the current status of trial NCT00116753?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 460 participants. The study started on 2005-01. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00116753?
The interventions under investigation include: Degarelix (DRUG).
Who is sponsoring clinical trial NCT00116753?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.